46P AB521, a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor, for the treatment of renal cell carcinoma
Titel:
46P AB521, a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor, for the treatment of renal cell carcinoma
Auteur:
Lawson, K.V. Sivick Gauthier, K.E. Piovesan, D. Mailyan, A. Mata, G. Fournier, J.T.A. Yu, K. Liu, S. Soriano, F. Jin, L. Ginn, E. Schweickert, P.G. Meleza, C.A. Pham, A. Seitz, L. Liao, K. Paterson, E. Foster, P. Walters, M.J. Leleti, M.